Key Impact
- Structured CER evidence input matrix and FDA-ready predicate comparison framework
- MDR + MEDDEV-aligned CER redesign
- Dedicated SOTA literature strategy
- Pre-market PMS / PMCF risk linkage plan
Client Overview
- Geography: India / US/ EU
- Company Type: MedTech product innovator
- Market Segment: Fluid monitoring and patient management systems
- Device Classification: FDA Class II (510(k)); EU MDR active medical device pathway
- Engagement Model: Clinical evidence planning, CER development, and Regulatory strategy.
Developed a regulatory and clinical evidence pathway, integrating FDA 510(k) substantial equivalence justification with EU MDR-compliant CER restructuring, SOTA strategy, and evidence planning for Multi geographical submission support.
Client is developing a Fluid Monitoring System intended for clinical fluid status monitoring and decision support. The engagement focused on building a dual-market evidence strategy: establishing FDA substantial equivalence through predicate comparison and restructuring the Clinical Evaluation Report to meet EU MDR scientific and systematic evaluation requirements before market release.
Business Challenge
The client required a clear commercialization pathway for US and EU markets, with immediate focus on predicate-based 510(k) feasibility and CER compliance upgrades to support future regulatory submissions.
Key compliance gaps identified included:
- Missing structured substantial equivalence comparison table
- Incomplete CER evidence input checklist
- Need for verbatim IFU referencing
- Absence of a dedicated State of the Art (SOTA) search strategy
- CER not fully aligned to Annex XIV Part A and MEDDEV Rev.4 flow
- Need to define risk, PMS, and PMCF linkage language despite pre-market stage
Our Approach
A CER-focused regulatory strategy was developed for the Fluid Monitoring System, centered on EU MDR/MEDDEV-aligned Clinical Evaluation Report development, supported by an FDA-ready substantial equivalence comparison framework, a robust clinical evidence input matrix, and a dedicated State of the Art literature methodology.
Results & Business Impact
- Established a submission-grade CER framework aligned to Annex XIV and MEDDEV
- Strengthened clinical evidence defensibility and benefit-risk justification
- Added forward-looking PMS / PMCF / RMF linkage for lifecycle compliance
- Accelerates US and EU market entry planning
From Predicate Strategy to MDR-Grade Clinical Evidence—Built for Faster Market Access
Our CER-focused clinical evidence support approach helps MedTech innovators transform early-stage evidence gaps into submission-ready Clinical Evaluation Reports. By combining literature appraisal, SOTA justification, clinical data analysis, benefit-risk evaluation, and predicate-supported evidence mapping, we build scientifically robust CERs that strengthen MDR submission readiness and long-term global market access.
